

# FDA approves ozempic for type 2 diabetes

6 December 2017

---

Copyright © 2017 [HealthDay](#). All rights reserved.



(HealthDay)—A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's [insulin production](#) and reduces appetite, the *Associated Press* reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 [diabetes patients](#) found those who took Ozempic had average reductions in long-term [blood glucose](#) levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the *AP* reported.

**More information:** [More Information](#)

APA citation: FDA approves ozempic for type 2 diabetes (2017, December 6) retrieved 4 June 2022 from <https://medicalxpress.com/news/2017-12-fda-ozempic-diabetes.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*